Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.210 +0.200 (+2.22%)
Streaming Delayed Price Updated: 10:22 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Via The Motley Fool
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars
Pharmaceutical company Organon (NYSE:OGN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.59 billion. The company expects the full year’s... 
Via StockStory
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look Ahead: Organon's Earnings Forecast
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Organon Earnings: What To Look For From OGN
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings this Tuesday before market hours. Here’s what you need to know. 
Via StockStory
Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Stocks Under $50 in the Doghouse
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results
Organon said that the mid-stage study evaluating its OG-6219 in endometriosis-related pain did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to... 
Via Stocktwits
2 Cash-Producing Stocks for Long-Term Investors and 1 to Think Twice About
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
1 Profitable Stock for Long-Term Investors and 2 to Be Wary Of
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Easy Income Portfolio: June 2025 Update
 
Via Benzinga
3 of Wall Street’s Favorite Stocks in Hot Water
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Government Stocks World Trade
3 Low-Volatility Stocks with Questionable Fundamentals
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
OGN Q1 Earnings Call: Revenue Exceeds Expectations Amid Strategic Focus on Deleveraging and Product Growth
Pharmaceutical company Organon (NYSE:OGN) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per... 
Via StockStory
Topics World Trade
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists
Organon shares sank 27% Thursday after slashing its dividend by over 90%, triggering analyst downgrades and investor concern. Some retail traders, however, remained upbeat, citing the company’s focus... 
Via Stocktwits
Topics World Trade
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Dow Surges Over 300 Points; McDonald's Posts Weak Revenue
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q1 But Stock Drops 23.5%
Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share... 
Via StockStory
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Organon (OGN) Q1 Earnings: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
3 Cash-Producing Stocks with Questionable Fundamentals
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.